TY - JOUR
T1 - Localization of monoclonal antibody auai and its F(ab')2 fragments in human tumour xenografts
T2 - An autoradiographic and immunohistochemical study
AU - Pervez, S.
AU - Epenetos, A. A.
AU - Mooi, W. J.
AU - Evans, D. J.
AU - Rowlinson, G.
AU - Dhokia, B.
AU - Krausz, T.
PY - 1988
Y1 - 1988
N2 - The mouse monoclonal antibody (MAb) AUAI, when applied on LoVo tumour sections, reacts by staining all tumour cells, on their cell surfaces. To investigate the accessibility of these sites to antibody when the tumour is present as a solid mass in vivo, subcutaneous xenografts of LoVo were first prepared in nude mice. The mice were then injected intravenously with either 125I‐labelled AUAI, 125I AUAI F(ab')2 or with 125I‐labelled HMFG2 (negative control antibody). Animals were killed at various time intervals. Gross and micro‐autoradiography as well as immunohistochemistry were performed on tissue samples of tumour and control organs. The in vivo injected antibody, in contrast to that studied in vitro, was localized only, as detected by auto radiography, on a thin layer of tumour cells adjacent to the vascularized stroma. On microscopically small tumour islands the antibody penetration was complete. Most of the radioactivity was on the cell surfaces, as seen on in vitro immunostaining. With intact antibody, similar autoradiographic results were obtained at days 1,3 and 6. With F(ab')2 fragments there was deeper penetration into the tumour at days 1 and 3, though less radioactivity was found; by day 6 the activity had greatly decreased. Radioactivity in the control organs was limited to the blood pool. Negative control antibody HMFG2 showed no localization on the tumour cells. These results were not due to differences in antigenic expression of the tumour cells but reflect the problem of accessibility of antigenic sites in vivo.
AB - The mouse monoclonal antibody (MAb) AUAI, when applied on LoVo tumour sections, reacts by staining all tumour cells, on their cell surfaces. To investigate the accessibility of these sites to antibody when the tumour is present as a solid mass in vivo, subcutaneous xenografts of LoVo were first prepared in nude mice. The mice were then injected intravenously with either 125I‐labelled AUAI, 125I AUAI F(ab')2 or with 125I‐labelled HMFG2 (negative control antibody). Animals were killed at various time intervals. Gross and micro‐autoradiography as well as immunohistochemistry were performed on tissue samples of tumour and control organs. The in vivo injected antibody, in contrast to that studied in vitro, was localized only, as detected by auto radiography, on a thin layer of tumour cells adjacent to the vascularized stroma. On microscopically small tumour islands the antibody penetration was complete. Most of the radioactivity was on the cell surfaces, as seen on in vitro immunostaining. With intact antibody, similar autoradiographic results were obtained at days 1,3 and 6. With F(ab')2 fragments there was deeper penetration into the tumour at days 1 and 3, though less radioactivity was found; by day 6 the activity had greatly decreased. Radioactivity in the control organs was limited to the blood pool. Negative control antibody HMFG2 showed no localization on the tumour cells. These results were not due to differences in antigenic expression of the tumour cells but reflect the problem of accessibility of antigenic sites in vivo.
UR - http://www.scopus.com/inward/record.url?scp=0024238235&partnerID=8YFLogxK
U2 - 10.1002/ijc.2910410806
DO - 10.1002/ijc.2910410806
M3 - Article
C2 - 3209296
AN - SCOPUS:0024238235
SN - 0020-7136
VL - 41
SP - 23
EP - 29
JO - International Journal of Cancer
JF - International Journal of Cancer
IS - 3 S
ER -